Synthetic human genome design and assembly
Designing and chemically building large human chromosomes or whole genomes from scratch, with predictable effects of redesigned sequences on development and physiology.
State of the art
Wellcome's £10M Synthetic Human Genome project (2025) targets a first synthetic human chromosome (~2% of the genome).
- Assembly and delivery of megabase DNA into mammalian cells is inefficient
- Cannot predict phenotype from designed sequence for complex traits like strength or intelligence
- Testing designs requires embryos and developmental models
Who’s working on it
- Jason ChinResearcherMRC Laboratory of Molecular Biology and the Generative Biology Institute, Ellison Institute of Technology, Oxford
Leads SynHG and previously built synthetic recoded E. coli genomes; his group is developing the assembly tools for megabase-scale human sequence
Five-year project launched June 2025 with GBP 10M from Wellcome across Cambridge, Kent, Manchester, Oxford and Imperial, targeting a first synthetic human chromosome (about 2 percent of the genome)
- Patrick Yizhi CaiResearcherUniversity of Manchester
Designed synthetic yeast chromosomes for Sc2.0 and is a SynHG co-investigator, bringing the only completed whole-eukaryotic-genome synthesis experience to the human effort
- Ansa Biotechnologies ↗Startup
Enzymatic DNA synthesis using TdT-nucleotide conjugates; now delivers 50 kb clonal DNA in 24 days at $0.28-0.38 per base pair after a $54.4M Series B in October 2025 ($134M total)
- Twist Bioscience ↗Company
The largest commercial supplier of synthetic DNA, whose silicon-based phosphoramidite platform sets the price per base that any genome-scale project must build on
- Care-full SynthesisProgram
Wellcome-funded social-science program led from the University of Kent running empirical studies with publics worldwide on large genome synthesis, deliberately started alongside the technical work
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| research | Megabase-scale DNA assembly and chromosome transplantation into human cell lines | $$ $10M – $100M |
| research | Genotype-to-phenotype models for polygenic traits validated in organoids and animals | $$$ $100M – $1B |
Depends on
Required by
No other capability builds on this directly.